BioVaxys Technology Corp.: Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process Development

VANCOUVER, BC, June 15, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices

Related Keywords

United States ,Canada ,United Kingdom ,France ,Vancouver ,British Columbia ,Frankfurt ,Brandenburg ,Germany ,British ,Canadian ,Bioelpida ,David Berd ,Davin Shinedling ,Kenneth Kovan ,Biovaxys Technology Corp ,Jba Inc ,Biovaxys Co ,Biovaxys Or Company ,Prnewswire Biovaxys Technology Corp ,Deaconess Research Institute ,Vaxys Technology ,Hospices Civils De Lyon ,Good Manufacturing Process ,Biovaxy Lyon Based ,Vaxys President ,Chief Operating Officer Kenneth Kovan ,Biovaxys Co Founder ,Chief Medical Officer David Berd ,British Columbia Registered ,Frankfurt Bourse ,Abiovaxys ,Technology ,Orp ,Linical ,Study ,Collaborator ,Ends ,First ,Surgically ,Excised ,Ovarian ,Dancer ,Rumors ,918 ,Vaccine ,Process ,Development ,